Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2000

View Archived Issues

FDA issues second approvable letter for mifepristone

Schwarz expands development pipeline during fourth quarter 1999

Statin inhibits VSMC proliferation, reduces neointimal formation after vascular injury

Alendronate nitrate: a new bisphosphonate salt with reduced GI toxicity

NicOx presents nitrate salts of respiratory medications with improved tolerance

Potential new AIDS vaccine designed at Erasmus

Asahi discloses 2,3-dihydrobenzofurans for emesis, etc.

Antigenic telomerase-derived proteins/peptides for cancer

First report of sequence-specific DNA dialkylation with diamide-CPI conjugate

Ixion's transplanted islet cells for diabetes featured in Nature Medicine

AAAAI news: icatibant effective in reducing antigen-induced nasal hyperresponsiveness in SAR

Phase I/II trial examines multiple doses of IL-4R in asthmatic patients

Prepulsid labeling revised in Canada

BLS files phase II ADHD Altropane study with FDA

Exploratory human studies with PNU-142731A reported at AAAAI meeting

Sweden approves Shire's AD treatment agent

Rupatadine inhibits TNF-alpha release, may have potential in late-phase allergic reactions

ABS-205 to be studied as potential Alzheimer's disease treatment

Study indicates therapeutic effects of cannabinoids in multiple sclerosis

Aventis discontinues development of propentofylline

In vitro and in vivo studies with specific chymase inhibitor suggest potential in atopic dermatitis

Immunomedics updates progress with genetically engineered cancer immunotherapy

Phase II SBIR grant awarded to 3-D for GPCRs

Genset and Abbott establish new agreement for disease gene discovery

Theseus Imaging's radiopharmaceutical useful in MI patients

C5 inhibitor prevents organ damage associated with GI ischemia in preclinical studies

Cel-Sci identifies new therapeutic AIDS vaccine